Cancer: Total metastasis and progression rate of prostate cancer in PLCO

the !---- prostate, lungs, colorectal, and ovarian (PLCO) cancer screening trials evaluated the effects of prostate-specific antigen screening and digital rectal examinations on prostate cancer mortalityanother research endpoint is the burden of total metastatic diseaseAll men in thePLCO assessed metastatic prostate cancer at the time of diagnosis; the total metastatic disease rate ofis defined as the metastasis (PYs) found at the time of diagnosis or by the metastasis found through progressthe rate ofmetastasis progression was calculated in men with clinical stage I/II prostate cancercompare the survival rate of men with metastasis at the time of diagnosis with those of men who were transferredresults showed that in the PLCO, there were 4,974 cases of prostate cancer and 4,699 cases of prostate cancer in the intervention group of 38,340 men and 38,343 men in the control groupThe total metastasis rates in theintervention group and control group were 4.72 and 4.83 per 10,000 PY (ratio ratio, 0.98; 95% CI, 0.81-1.18)The rate of metastasis progression in theintervention group and men with stage I/II prostate cancer in the control group was 43.7 and 50.5 per 10,000 PYs, respectively (P -30)prostate cancer-specific 5- and 10-year survival rates, men with metastatic progression (24 percent and 19 percent, respectively) were significantly worse than men with metastasis at the time of diagnosis (40 percent and 26 percent, respectively)the above, the results show that the total metastasis rate of each arm in PLCO is similar to the rate of transfer progressionmen with metastatic progress imetancy had a worse survival rate than men with metastatic disease at the time of diagnosis